Jia Jie Biomedical (4109) reported revenue of NT$42.1 million for Oct 2026, +8.0% year on year and -15.7% from the previous month. Revenue for Jan–Oct 2026 was NT$452.8 million (+16.0% year on year).
Year-on-year revenue growth: 7 months in a row. →
In Oct 2026, it ranked No. 105 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$42.1 million | +8.0% | -15.7% |
| Sep 2026 | NT$49.9 million | +38.1% | +13.2% |
| Aug 2026 | NT$44.1 million | +13.9% | -9.6% |
| Jul 2026 | NT$48.7 million | +33.3% | -1.2% |
| Jun 2026 | NT$49.3 million | +40.4% | +24.4% |
| May 2026 | NT$39.6 million | +13.2% | -9.5% |
| Apr 2026 | NT$43.8 million | +17.7% | -30.7% |
| Mar 2026 | NT$63.2 million | -10.0% | +83.7% |
| Feb 2026 | NT$34.4 million | +11.2% | -8.6% |
| Jan 2026 | NT$37.7 million | +19.3% | -34.3% |
| Dec 2025 | NT$57.3 million | -6.3% | +57.9% |
| Nov 2025 | NT$36.3 million | +8.6% | -6.9% |
| Oct 2025 | NT$39 million | +13.5% | +7.8% |
| Sep 2025 | NT$36.1 million | +19.5% | -6.6% |
| Aug 2025 | NT$38.7 million | +15.1% | +5.8% |
| Jul 2025 | NT$36.5 million | +19.6% | +4.0% |
| Jun 2025 | NT$35.1 million | -51.1% | +0.4% |
| May 2025 | NT$35 million | -21.3% | -6.0% |
| Apr 2025 | NT$37.2 million | +2.8% | -47.0% |
| Mar 2025 | NT$70.2 million | +19.3% | +127.0% |
| Feb 2025 | NT$30.9 million | -46.3% | -2.0% |
| Jan 2025 | NT$31.6 million | -27.1% | -48.4% |
| Dec 2024 | NT$61.2 million | +147.1% | +83.0% |
| Nov 2024 | NT$33.4 million | -2.2% | -2.6% |
| Oct 2024 | NT$34.3 million | +33.8% | +13.5% |
Jan–Oct 2026 cumulative: NT$452.8 million (+16.0% YoY)
Other Biotech & Medical companies
Compare with peers: Jia Jie Biomedical vs PEC / Jia Jie Biomedical vs Lotus Pharm / Jia Jie Biomedical vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16